Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Cord Blood-Derived Treatment Shows Promise in Blood Cancer

January 25th 2024, 8:00pm

Article

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

‘Remarkable’ Results from Tecartus in Patients With R/R MCL

January 4th 2024, 10:00pm

Article

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

Tecartus Induces Responses in Real-World Population of High-Risk R/R MCL

December 10th 2023, 12:25am

Article

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Encouraging Trial Results Announced for Breyanzi in Lymphoma Treatment

May 17th 2023, 9:00pm

Article

Breyanzi has reportedly shown promising effects for patients with relapsed or refractory follicular lymphoma and B-cell non-Hodgkin lymphoma.

Pharma Companies Pull Imbruvica Indication for Marginal Zone and Mantle Cell Lymphoma

April 7th 2023, 9:00pm

Article

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma.

FDA Approvals From Winter 2023 You May Have Missed

March 21st 2023, 3:00pm

Article

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Jaypirca FDA Approval a 'Major Breakthrough' for Mantle Cell Lymphoma

February 21st 2023, 8:00pm

Article

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

FDA Approves Jaypirca for Relapsed/Refractory Mantle Cell Lymphoma

January 27th 2023, 8:10pm

Article

The Food and Drug Administration approved Jaypirca for patients with relapsed/refractory mantle cell lymphoma who have been previously treated with multiple lines of therapy.

Avoiding Unavoidable Carcinogens

January 4th 2023, 4:00pm

Article

We need to learn more about how to potentially lessen toxins' effects on people's lives.

Patients With Mantle Cell Lymphoma Continue to Respond to Tecartus Three Years Later

June 22nd 2022, 1:00pm

Article

Long-term follow-up shows that the CAR-T cell therapy Tecartus continues to elicit durable responses in patients with relapsed/refractory mantle cell lymphoma.